A phase iii, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder

1. Herschorn, S.
2. Barkin, J.
3. Castro-Diaz, D.
4. Frankel, J.M.
5. Espuna-Pons, M.
6. Gousse, A.E.
7. Stölzel, M.
8. Martin, N.
9. Gunther, A.
10. Van Kerrebroeck, P.